Francesco Forconi, MD, DM, PhD, FRCPath, University of Southampton, Southampton, UK, discusses the VENICE-1 trial (NCT02756611), an international study evaluating venetoclax monotherapy in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). With a median follow-up of 50 months, the trial reported a complete remission (CR) rate of 35% in B-cell receptor inhibitor-naïve patients and 27% in those previously exposed to B-cell receptor inhibitors. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
